AGIOS PHARMACEUTICALS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
AGIOS PHARMACEUTICALS, INC. (AGIO) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $15.94 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-07-30
- AGIOS PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $15.94M, a 8.50% increase year-over-year.
- AGIOS PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $15.54M, a 36.82% increase year-over-year.
- AGIOS PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $12.38M, a 11.05% increase year-over-year.
- AGIOS PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $14.69M, a 27.04% increase year-over-year.
- AGIOS PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $52.55M, a 22.65% increase from fiscal 2024.
- AGIOS PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $42.85M, a 4.29% decline from fiscal 2023.
- AGIOS PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $44.77M, a 9.19% decline from fiscal 2022.
- AGIOS PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $49.30M, a 7.87% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $15.94M 10-Q · filed 2026-07-30 | $31.48M derived: sum of 2 quarters · filed 2026-07-30 | ||||
| 2026-03-31 | $15.54M 10-Q · filed 2026-07-30 | |||||
| 2025-12-31 | $52.55M 10-K · filed 2026-02-12 | |||||
| 2025-09-30 | $12.38M 10-Q · filed 2025-10-30 | $27.07M derived: sum of 2 quarters · filed 2026-07-30 | $38.43M derived: sum of 3 quarters · filed 2026-07-30 | |||
| 2025-06-30 | $14.69M 10-Q · filed 2026-07-30 | $26.05M derived: sum of 2 quarters · filed 2026-07-30 | ||||
| 2025-03-31 | $11.36M 10-Q · filed 2026-07-30 | |||||
| 2024-12-31 | $42.85M 10-K · filed 2026-02-12 | |||||
| 2024-09-30 | $11.14M 10-Q · filed 2025-10-30 | $22.71M derived: sum of 2 quarters · filed 2025-10-30 | $31.94M derived: sum of 3 quarters · filed 2025-10-30 | |||
| 2024-06-30 | $11.56M 10-Q · filed 2025-10-30 | $20.80M derived: sum of 2 quarters · filed 2025-10-30 | ||||
| 2024-03-31 | $9.23M 10-Q · filed 2025-10-30 | |||||
| 2023-12-31 | $44.77M 10-K · filed 2026-02-12 | |||||
| 2023-09-30 | $9.08M 10-Q · filed 2024-10-31 | $20.81M derived: sum of 2 quarters · filed 2024-10-31 | $30.95M derived: sum of 3 quarters · filed 2024-10-31 | |||
| 2023-06-30 | $11.74M 10-Q · filed 2024-10-31 | $21.88M derived: sum of 2 quarters · filed 2024-10-31 | ||||
| 2023-03-31 | $10.14M 10-Q · filed 2024-10-31 | |||||
| 2022-12-31 | $49.30M 10-K · filed 2025-02-13 | |||||
| 2022-09-30 | $11.16M 10-Q · filed 2023-11-02 | $22.32M derived: sum of 2 quarters · filed 2023-11-02 | $37.83M derived: sum of 3 quarters · filed 2023-11-02 | |||
| 2022-06-30 | $11.16M 10-Q · filed 2023-11-02 | $26.68M derived: sum of 2 quarters · filed 2023-11-02 | ||||
| 2022-03-31 | $15.51M 10-Q · filed 2023-11-02 | |||||
| 2021-12-31 | $53.51M 10-K · filed 2024-02-15 | |||||
| 2021-09-30 | $12.15M 10-Q · filed 2022-11-03 | $27.03M derived: sum of 2 quarters · filed 2022-11-03 | $41.89M derived: sum of 3 quarters · filed 2022-11-03 | |||
| 2021-06-30 | $14.88M 10-Q · filed 2022-11-03 | $29.74M derived: sum of 2 quarters · filed 2022-11-03 | ||||
| 2021-03-31 | $14.85M 10-Q · filed 2022-11-03 | |||||
| 2020-12-31 | $61.60M 10-K · filed 2023-02-23 | $75.12M 10-K · filed 2021-02-25 | ||||
| 2020-09-30 | $14.98M 10-Q · filed 2021-11-03 | $18.41M 10-Q · filed 2020-11-05 | $32.59M derived: sum of 2 quarters · filed 2021-11-03 | $48.26M derived: sum of 3 quarters · filed 2021-11-03 | ||
| 2020-06-30 | $17.61M 10-Q · filed 2021-11-03 | $20.43M 10-Q · filed 2020-07-30 | $33.28M derived: sum of 2 quarters · filed 2021-11-03 | |||
| 2020-03-31 | $15.67M 10-Q · filed 2021-11-03 | $19.69M 10-Q · filed 2020-04-30 | ||||
| 2019-12-31 | $58.05M 10-K · filed 2022-02-24 | $72.37M 10-K · filed 2020-02-19 | ||||
| 2019-09-30 | $18.59M 10-Q · filed 2020-11-05 | $37.13M derived: sum of 2 quarters · filed 2020-11-05 | $55.24M derived: sum of 3 quarters · filed 2020-11-05 | |||
| 2019-06-30 | $18.55M 10-Q · filed 2020-11-05 | $36.66M derived: sum of 2 quarters · filed 2020-11-05 | ||||
| 2019-03-31 | $18.11M 10-Q · filed 2020-11-05 | |||||
| 2018-12-31 | $73.36M 10-K · filed 2021-02-25 | |||||
| 2018-09-30 | $24.19M 10-Q · filed 2019-10-31 | $40.65M derived: sum of 2 quarters · filed 2019-10-31 | $55.17M derived: sum of 3 quarters · filed 2019-10-31 | |||
| 2018-06-30 | $16.45M 10-Q · filed 2019-10-31 | $30.98M derived: sum of 2 quarters · filed 2019-10-31 | ||||
| 2018-03-31 | $14.52M 10-Q · filed 2019-10-31 | |||||
| 2017-12-31 | $47.81M 10-K · filed 2020-02-19 | |||||
| 2016-12-31 | $42.09M 10-K · filed 2019-02-14 | |||||
| 2015-12-31 | $31.57M 10-K · filed 2018-02-14 | |||||
| 2014-12-31 | $11.51M 10-K · filed 2017-02-16 | |||||
| 2013-12-31 | $3.03M 10-K · filed 2016-02-26 | |||||
| 2012-12-31 | $742.00K 10-K · filed 2015-02-24 | |||||
| 2011-12-31 | $371.00K 10-K · filed 2014-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |